Overview

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Status:
Not yet recruiting
Trial end date:
2024-11-18
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm study to study the safety, efficacy and tolerability of Pemigatinib when used on participants with squamous or nonsquamous NSCLC with a documented FGFR1-3 mutations or fusions/rearrangement who have progressed on prior therapies and have no available standard treatment options
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation